Cargando…

Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report

Even in 2021, coronavirus disease 2019 (COVID-19) remains a major global health concern, especially in developing countries. The burden of this disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which affects not only primary respiratory but also other organ systems, ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Vukoja, Damir, Jurić, Andrea, Erkapić, Zdravka, Pejić, Tomislav, Zovko, Željko, Juričić, Josipa, Pejić, Jelena, Ćorluka, Matea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387596/
https://www.ncbi.nlm.nih.gov/pubmed/34456719
http://dx.doi.org/10.3389/fphar.2021.684537
_version_ 1783742475323572224
author Vukoja, Damir
Jurić, Andrea
Erkapić, Zdravka
Pejić, Tomislav
Zovko, Željko
Juričić, Josipa
Pejić, Jelena
Ćorluka, Matea
author_facet Vukoja, Damir
Jurić, Andrea
Erkapić, Zdravka
Pejić, Tomislav
Zovko, Željko
Juričić, Josipa
Pejić, Jelena
Ćorluka, Matea
author_sort Vukoja, Damir
collection PubMed
description Even in 2021, coronavirus disease 2019 (COVID-19) remains a major global health concern, especially in developing countries. The burden of this disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which affects not only primary respiratory but also other organ systems, keeps rising as the pandemic continues. Primary health care centers are the first line where COVID-19 patients are managed and should be able to manage the vast majority of them successfully. In this paper, we present a case series and concept of beneficial management of even deteriorating and severe patients treated entirely in our primary health center. The management is based on well-timed and rational dexamethasone use, as well as on various other pharmacological and nonpharmacological treatments and interventions, and is supported by provided statistical data. According to the presented experience and positive outcomes achieved, it seems that even deteriorating and severe COVID-19 patients can be treated successfully to some extent or even completely in primary care settings. This kind of approach could be particularly beneficial in conditions of overload of higher-level health care institutions.
format Online
Article
Text
id pubmed-8387596
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83875962021-08-27 Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report Vukoja, Damir Jurić, Andrea Erkapić, Zdravka Pejić, Tomislav Zovko, Željko Juričić, Josipa Pejić, Jelena Ćorluka, Matea Front Pharmacol Pharmacology Even in 2021, coronavirus disease 2019 (COVID-19) remains a major global health concern, especially in developing countries. The burden of this disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which affects not only primary respiratory but also other organ systems, keeps rising as the pandemic continues. Primary health care centers are the first line where COVID-19 patients are managed and should be able to manage the vast majority of them successfully. In this paper, we present a case series and concept of beneficial management of even deteriorating and severe patients treated entirely in our primary health center. The management is based on well-timed and rational dexamethasone use, as well as on various other pharmacological and nonpharmacological treatments and interventions, and is supported by provided statistical data. According to the presented experience and positive outcomes achieved, it seems that even deteriorating and severe COVID-19 patients can be treated successfully to some extent or even completely in primary care settings. This kind of approach could be particularly beneficial in conditions of overload of higher-level health care institutions. Frontiers Media S.A. 2021-08-12 /pmc/articles/PMC8387596/ /pubmed/34456719 http://dx.doi.org/10.3389/fphar.2021.684537 Text en Copyright © 2021 Vukoja, Jurić, Erkapić, Pejić, Zovko, Juričić, Pejić and Ćorluka. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Vukoja, Damir
Jurić, Andrea
Erkapić, Zdravka
Pejić, Tomislav
Zovko, Željko
Juričić, Josipa
Pejić, Jelena
Ćorluka, Matea
Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report
title Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report
title_full Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report
title_fullStr Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report
title_full_unstemmed Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report
title_short Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen—Case Series Report
title_sort beneficial treatment outcomes of severe covid-19 patients treated entirely in primary care settings with dexamethasone including regimen—case series report
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387596/
https://www.ncbi.nlm.nih.gov/pubmed/34456719
http://dx.doi.org/10.3389/fphar.2021.684537
work_keys_str_mv AT vukojadamir beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport
AT juricandrea beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport
AT erkapiczdravka beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport
AT pejictomislav beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport
AT zovkozeljko beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport
AT juricicjosipa beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport
AT pejicjelena beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport
AT corlukamatea beneficialtreatmentoutcomesofseverecovid19patientstreatedentirelyinprimarycaresettingswithdexamethasoneincludingregimencaseseriesreport